At a glance
ClinicalIndex Comparison RecordPhase 2Active· 196 target
Drug / intervention
MHB039Adrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study of MHB039A for Advanced Solid Tumor to Evaluate the Efficacy and Safety
In Brief
A Phase 2 clinical trial evaluating MHB039A for Advanced Solid Tumor. Active but no longer recruiting, targeting 196 participants across 1 site.
Detailed Summary
Phase I/II open label, multicenter study to evaluate the efficacy and safety of MHB039A in advanced malignant tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumor
CountriesChina
Collaborators--
Timeline
Phase 2Active
20252026202720282029
First PostedApr 2024
Enrollment StartApr 2024
TodayJul 2026
Primary CompletionApr 2028
Study CompletionJun 2029
First PostedApr 3, 2024
Enrollment StartApr 16, 2024
Primary CompletionApr 1, 2028
Study CompletionJun 1, 2029
TodayJul 1, 2026
Enrollment to primary: 4.0 yearsPosted 2.2 years agoPrimary completion in 1.8 years
Interventions
MHB039Adrug
a bispecific antibody